INFIQ (Infinity Pharmaceuticals) EBITDA Margin %: -1,681.82% (As of Jun. 2023)


INFIQ Infinity Pharmaceuticals Inc INFIQ
16 GF Score
Price $0.00
View Full Analysis

What is Infinity Pharmaceuticals EBITDA Margin %?

Infinity Pharmaceuticals INFIQ -99.00% 16 EBITDA Margin % is -1,681.82% as of Jun. 2023. GuruFocus rates INFIQ with a GF Score™ of 16/100.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Infinity Pharmaceuticals's EBITDA for the three months ended in Jun. 2023 was $-9.81 Mil. Infinity Pharmaceuticals's Revenue for the three months ended in Jun. 2023 was $0.58 Mil. Therefore, Infinity Pharmaceuticals's EBITDA margin for the quarter that ended in Jun. 2023 was -1,681.82%.

Infinity Pharmaceuticals  (OTCPK:INFIQ) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Infinity Pharmaceuticals EBITDA Margin % Related Terms

Infinity Pharmaceuticals EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Infinity Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Infinity Pharmaceuticals EBITDA Margin % Chart

Infinity Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -49.53 -1,453.89 -2,185.22 -2,400.54 -1,686.50

Infinity Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,723.18 -1,483.29 -1,672.01 -1,490.42 -1,681.82

INFIQ vs CLCS, RVLPQ, IVRN: EBITDA Margin % Comparison

For the Biotechnology subindustry, Infinity Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Infinity Pharmaceuticals EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infinity Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Infinity Pharmaceuticals's EBITDA Margin % falls into.


INFIQ
16GF Score
Infinity Pharmaceuticals Inc INFIQ
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Infinity Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Infinity Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-43.731/2.593
=-1,686.50 %

Infinity Pharmaceuticals's EBITDA Margin % for the quarter that ended in Jun. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=-9.805/0.583
=-1,681.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -1,681.82% mean?
Infinity Pharmaceuticals (INFIQ) has a EBITDA Margin % of -1,681.82% as of Jun. 2023. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Infinity Pharmaceuticals and its competitors.
Is Infinity Pharmaceuticals' EBITDA Margin % too high?
Infinity Pharmaceuticals' current EBITDA Margin % is -1,681.82%. Overall, Infinity Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Infinity Pharmaceuticals' EBITDA Margin % compare to CLCS and RVLPQ?
Infinity Pharmaceuticals' EBITDA Margin % of -1,681.82% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Infinity Pharmaceuticals and its competitors. Infinity Pharmaceuticals's current EBITDA Margin % is -1,681.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infinity Pharmaceuticals stock overvalued right now?
Infinity Pharmaceuticals (INFIQ) has a current EBITDA Margin % of -1,681.82%. The current EBITDA Margin % is -1,681.82%. Infinity Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Infinity Pharmaceuticals (INFIQ), the current EBITDA Margin % is -1,681.82% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Infinity Pharmaceuticals Business Description

Address 1100 Massachusetts Avenue, Floor 4, Cambridge, MA, USA, 02138
Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company dedicated to developing novel medicines for people with cancer. It combines proven scientific expertise with a passion for developing novel small molecule drugs that target disease pathways for potential applications in oncology. It is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma, or PI3K-gamma.
16GF Score

Get the complete analysis for INFIQ

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price